Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLBE | ISIN: SE0012675361 | Ticker-Symbol: 6IRA
Frankfurt
05.06.25 | 08:15
0,644 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IRLAB THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
IRLAB THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur IRLAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiIRLAB Therapeutics: IRLAB Participates in Aktiespararna's Event - Aktiedagarna170GOTHENBURG, SE / ACCESS Newswire / June 4, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, June 4, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
28.05.IRLAB Therapeutics: IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757517GOTHENBURG, SE / ACCESS Newswire / May 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers...
► Artikel lesen
15.05.IRLAB Therapeutics: IRLAB to Present at BioStock Global Forum 2025220GOTHENBURG, SE / ACCESS Newswire / May 15, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 15, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers...
► Artikel lesen
13.05.IRLAB Therapeutics: IRLAB is Granted a Patent Expanding the Patent Protection for the Drug Candidate Mesdopetam in the US252GOTHENBURG, SE / ACCESS Newswire / May 13, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 13, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
12.05.Notice to the Annual General Meeting in IRLAB Therapeutics AB212GOTHENBURG, SE / ACCESS Newswire / May 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB, reg. no. 556931-4692 ("IRLAB" or the "Company"), holds its Annual General Meeting...
► Artikel lesen
07.05.IRLAB Therapeutics: IRLAB Publishes Interim Report for the Period January - March 2025245GOTHENBURG, SE / ACCESS Newswire / May 7, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that...
► Artikel lesen
06.05.IRLAB Therapeutics: IRLAB: Invitation to the Interim Report for Q1 2025 Presentation and Webcast246GOTHENBURG, SE / ACCESS Newswire / May 6, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, May 6, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
IRLAB THERAPEUTICS Aktie jetzt für 0€ handeln
25.04.IRLAB Therapeutics: IRLAB publishes the Annual Report for 2024357GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 25, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...
► Artikel lesen
07.04.IRLAB Therapeutics: IRLAB Presents at Two Redeye Events317GOTHENBURG, SE / ACCESS Newswire / April 7, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announces that...
► Artikel lesen
01.04.IRLAB Therapeutics: IRLAB to Present Clinical and Preclinical Data at the AD/PD 2025: 19th International Conference on Alzheimer's & Parkinson's Diseases297GOTHENBURG, SE / ACCESS Newswire / April 1, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Gothenburg, Sweden, April 1, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering...
► Artikel lesen
28.03.IRLAB Therapeutics: IRLAB Provides Additional Efficacy Data from the Phase IIb Study of Pirepemat in Patients with Parkinson's Disease769GOTHENBURG, SE / ACCESS Newswire / March 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that...
► Artikel lesen
27.03.IRLAB Therapeutics - Next steps laid out for IRL757357IRLAB has confirmed that clinical candidate IRL757, which has been designed to address apathy in patients with neurodegenerative conditions, will proceed to the next stages of clinical development....
► Artikel lesen
27.03.IRLAB Therapeutics: IRLAB to Initiate a Study of IRL757 in Parkinsons's Disease with Full Financial Backing from its Development Partner MSRD323ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GOTHENBURG, SE / ACCESS Newswire / March 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company...
► Artikel lesen
12.03.IRLAB (OMX: IRLAB-A) publishes preclinical mesdopetam data in journal419IRLAB Therapeutics has announced the publication of preclinical data on mesdopetam in the prestigious peer-reviewed journal, European Journal of Neuroscience. The research provided insights into the...
► Artikel lesen
12.03.IRLAB Therapeutics: IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience233GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and...
► Artikel lesen
11.03.IRLAB Therapeutics: IRLAB Participates in Stora Aktiedagarna262GOTHENBURG, SE / ACCESS Newswire / March 11, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease...
► Artikel lesen
05.03.IRLAB Therapeutics (OMX: IRLAB-A) misses primary endpoint with pirepemat363IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its second most clinically advanced asset, pirepemat, as a potential treatment for falls related to Parkinson's...
► Artikel lesen
05.03.IRLAB Therapeutics: IRLAB Reports Topline Results from a Phase IIb Study of Pirepemat in Patients with Parkinson's Disease353GOTHENBURG, SE / ACCESS Newswire / March 5, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's disease...
► Artikel lesen
27.02.IRLAB (OMX: IRLAB-A) publishes Phase IIb mesdopetam results in journal326IRLAB Therapeutics has announced that the results from its Phase IIb clinical trial, evaluating mesdopetam as a potential treatment to address levodopa induced dyskinesias, have been published in the...
► Artikel lesen
27.02.IRLAB Therapeutics: IRLAB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice551GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company...
► Artikel lesen
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1